GSK partners with A*STAR for reformulations

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) partnered with the Institute of Chemical and Engineering Sciences (ICES) at the Alliance for Science, Technology and Research (A*STAR) (Singapore) to develop "evidence based formulation" (EBF) products for emerging markets. The companies said EBFs are reformulated drugs, including fixed-dose combinations of active drugs or formulations with different pharmacokinetic properties, routes of delivery or improved safety profiles. GSK and A*STAR said the five-year deal will leverage ICES's expertise in synthesis, drug product formulation, process development and scale-up. The partners could not be reached for details. ...